title: [Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
abstract: A novel molecular targeting drug, a proteasome inhibitor, bortezomib (Bor), has been reported to be highly effective for relapsed/refractory, as well as for newly diagnosed multiple myeloma, but is also associated with a high frequency of herpes zoster (HZ) infection (13%). We conducted a retrospective survey on HZ infection (profile) after Bor therapy in our hospital. Six of 30 patients developed HZ infection during bortezomib-dexamethasone treatment (BD therapy). Age, performance status, and stem cell transplantation were not related risk factors for HZ infection. HZ developed when acyclovir (ACV) was not administrated to all six cases. Continuous administration of ACV decreased the incidence of HZ infection. Based on these results, we started an anti- HZ prophylaxis program using ACV for all patients receiving BD therapy. Further study is warranted to establish the optimal dose and duration of ACV for appropriate prophylaxis of HZ infection.
authors: Pharmaceutical Division, Niigata Cancer Center Hospital.
authors: Yoshimi
authors: Y
authors: Hasegawa
authors: Fumiko
authors: F
authors: Kawahara
authors: Haruki
authors: H
authors: Nagai
authors: Takayuki
authors: T
authors: Hirose
authors: Yosuke
authors: Y
authors: Imai
authors: Takuro
authors: T
authors: Ishiguro
authors: Takaaki
authors: T
authors: Chou
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006562:Herpes Zoster / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D000212:Acyclovir